Month: March 2024

First Quarter Revenues and Earnings Per Share Ahead of Estimates BURLINGTON, Mass., March 26, 2024 (GLOBE NEWSWIRE) — Progress (Nasdaq: PRGS), the trusted provider of infrastructure software, today announced financial results for its fiscal first quarter ended February 29, 2024. First Quarter 2024 Highlights¹:Revenue of $185 million increased 12% year-over-year on both an actual and a constant currency basis. Non-GAAP revenue of $185 million increased 12% year-over-year on an actual currency basis and 11% on a constant currency basis. Annualized Recurring Revenue (“ARR”) of $571 million remained consistent year-over-year on a constant currency basis. Operating margin was 19% and non-GAAP operating margin was 42%. Diluted earnings per share was $0.51 compared to $0.53 in the same quarter last year, a decrease of 4%.  Non-GAAP...

MINNEAPOLIS, March 26, 2024 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter and full year ended December 31, 2023. As previously announced, management is hosting earnings call today at 4:30 p.m. ET. 2023 and early 2024 Highlights: CollaborationsDivestiture of Assets within Eflornithine (DFMO) Pediatric Neuroblastoma Program to US WorldMeds – Panbela to receive up to $9.5 Million Entered into Sponsored Research Agreement with MD Anderson Cancer Center to Evaluate Polyamine Metabolic Inhibitor Therapy in Combination with CAR-T Cell Therapy and bispecific monoclonal antibodies New Research Agreement with Johns Hopkins...

Conference Call on Tuesday, March 26, 2024, at 9 p.m. ET with Accompanying Investor Presentation BEIJING, China, March 26, 2024 (GLOBE NEWSWIRE) — ATA Creativity Global (“ACG” or the “Company”, Nasdaq: AACG), an international educational services company focused on providing quality learning experiences that cultivate and enhance students’ creativity, today announced preliminary unaudited financial results for the quarter and year ended December 31, 2023 (“Fourth Quarter 2023” and “Fiscal Year 2023”, respectively). Fourth Quarter 2023 and Fiscal Year 2023 HighlightsDuring Fourth Quarter 2023, student enrollment was 1,011, an increase of 11.3% from 908 in the prior-year period. Of the 1,011 students, 648 were enrolled in ACG’s portfolio training programs, compared to 574 in the prior-year period. 48,421 portfolio training credit...

Revenue at high end of guidance range Well-positioned for Q2 with a strong pipeline Confirming full year business outlook for revenue, profit, cash flow Committed to share repurchases of $100 million over remainder of 2024NEWARK, Calif., March 26, 2024 (GLOBE NEWSWIRE) — Concentrix Corporation (NASDAQ: CNXC), a leading global provider of customer experience (CX) solutions and technology, today announced financial results for the fiscal first quarter ended February 29, 2024.  Three Months Ended      February 29, 2024   February 28, 2023   ChangeRevenue ($M) $ 2,402.7     $ 1,636.4     46.8%Operating income ($M) $ 148.4     $ 156.0     (4.9)%Non-GAAP operating income ($M) (1) $ 319.1     $ 217.6     46.6%Operating margin   6.2 %     9.5 %   -330 bpsNon-GAAP operating margin (1)   13.3 %     13.3 %   0 bpsNet...

Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy (GA) Expected in mid-2024, a Global Sham-Controlled Trial Using Vision Preservation as Primary Outcome Measure Clinical Proof-of-Concept Data with ANX1502 Oral Inhibitor of the Classical Pathway Expected in Second Half of 2024 Robust Balance Sheet with Cash, Cash Equivalents, and Short-term Investments of Approximately $260 Million as of December 31, 2023, and Anticipated Runway into mid-2026 BRISBANE, Calif., March 26, 2024 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body,...

All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial Results demonstrated targeted drug delivery and absorption in the colon, with 3-4 times lower drug levels in blood Remainder of BT-600 clinical trial progressing well and on schedule Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2023. “We are thrilled by the results from the single ascending dose (SAD) portion of our clinical trial for BT-600. The data indicate exactly what we had hoped: NaviCap devices consistently delivered tofacitinib...

GRAPEVINE, Texas, March 26, 2024 (GLOBE NEWSWIRE) — GameStop Corp. (NYSE: GME) (“GameStop” or the “Company”) today released financial results for the fourth quarter and fiscal year ended February 3, 2024. The Company’s consolidated financial statements, including GAAP and non-GAAP results, are below. The Company’s Form 10-K and supplemental information can be found at https://investor.gamestop.com. FOURTH QUARTER OVERVIEWNet sales were $1.794 billion for the fourth quarter, compared to $2.226 billion in the prior year’s fourth quarter. Selling, general and administrative (“SG&A”) expenses were $359.2 million, or 20.0% of net sales, for the fourth quarter, compared to $453.4 million, or 20.4% of net sales, in the prior year’s fourth quarter. Net income was $63.1 million for the fourth quarter, compared to net...

WINNIPEG, Manitoba, March 26, 2024 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its fourth quarter and full year 2023 financial results. On December 20, 2023, Kane Biotech announced that it received a non-binding offer for its interest in STEM Animal Health. The terms of the offer remain confidential but specify that Kane will sell its ownership of STEM. In addition, pursuant to the terms of the offer, Kane received a US $625,000 deposit. The parties have agreed to collaborate using their best efforts to enter into a binding share purchase agreement with respect to the sale of STEM within 90 days. On March 20, 2024, Kane announced that it has extended the exclusivity period from March 19, 2024 until March 31, 2024 and that it has received additional deposits totaling...